Factor VIII replacement is still the standard of care in haemophilia A

被引：95
作者：
Aledort, Louis [1 ]
Mannucci, Pier Mannuccio [2 ]
Schramm, Wolfgang [3 ]
Tarantino, Michael [4 ,5 ]
机构：
[1] Icahn Sch Med Mt Sinai, Div Hematol Oncol, New York, NY 10029 USA
[2] IRCCS Fdn Ca Granda Maggiore Policlin Hosp, Sci Direct, Via Pace 9, I-20122 Milan, Italy
[3] Univ Hosp Munich, Dept Transfus Med & Haemostasis, Munich, Germany
[4] Univ Illinois, Coll Med, Peoria, IL 61656 USA
[5] Bleeding & Clotting Disorders Inst, Peoria, IL USA
来源：
BLOOD TRANSFUSION | 2019年 / 17卷 / 06期
关键词：
factor VIII; haemophilia A; prophylaxis; standard of care; half-life; RECOMBINANT FACTOR-VIII; FC FUSION PROTEIN; EXTENDED-HALF-LIFE; BAY; 94-9027; EMICIZUMAB PROPHYLAXIS; BISPECIFIC ANTIBODY; IMMUNE TOLERANCE; FULL-LENGTH; ON-DEMAND; SAFETY;
D O I：
10.2450/2019.0211-19
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Prophylactic factor VIII (FVIII) has dramatically improved haemophilia A treatment, preventing joint bleeding and halting the deterioration of joint status. FVIII products with an extended plasma half-life further improve patients' quality of life and increase therapeutic adherence. New licensed classes of non-replacement products include prophylactic emicizumab, which is administered subcutaneously up to every 4 weeks. However, this drug is not suitable for acute bleeding episodes or management of major surgery, and long-term data on the impact of emicizumab on joint health, FVIII inhibitor development and thrombotic risk are awaited. Prophylaxis with FVIII replacement remains the standard of care in haemophilia A, with the aim of achieving a level of haemostasis control that allows patients to meet their lifestyle goals.
引用
收藏
页码：479 / 486
页数：8
相关论文
共 69 条
  • [1] A LONGITUDINAL-STUDY OF ORTHOPEDIC OUTCOMES FOR SEVERE FACTOR-VIII-DEFICIENT HEMOPHILIACS
    ALEDORT, LM
    HASCHMEYER, RH
    PETTERSSON, H
    EIBL, H
    GILBERT, M
    HILGARTNER, M
    KUNSHACK, M
    LARRIEU, MJ
    LEVINE, P
    [J]. JOURNAL OF INTERNAL MEDICINE, 1994, 236 (04) : 391 - 399
  • [2] Intracranial haemorrhage in children and adolescents with severe haemophilia A or B - the impact of prophylactic treatment
    Andersson, Nadine G.
    Auerswald, Guenter
    Barnes, Chris
    Carcao, Manuel
    Dunn, Amy L.
    Fijnvandraat, Karin
    Hoffmann, Marianne
    Kavakli, Kaan
    Kenet, Gili
    Kobelt, Rainer
    Kurnik, Karin
    Liesner, Ri
    Makipernaa, Anne
    Manco-Johnson, Marilyn J.
    Mancuso, Maria E.
    Molinari, Angelo C.
    Nolan, Beatrice
    Perez Garrido, Rosario
    Petrini, Pia
    Platokouki, Helen E.
    Shapiro, Amy D.
    Wu, Runhui
    Ljung, Rolf
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2017, 179 (02) : 298 - 307
  • [3] [Anonymous], [No title captured]
  • [4] Factor VIII: Long-established role in haemophilia A and emerging evidence beyond haemostasis
    Bannow, Bethany Samuelson
    Recht, Michael
    Negrier, Claude
    Hermans, Cedric
    Berntorp, Erik
    Eichler, Hermann
    Mancuso, Maria Elisa
    Klamroth, Robert
    O'Hara, Jamie
    Santagostino, Elena
    Matsushita, Tadashi
    Kessler, Craig
    [J]. BLOOD REVIEWS, 2019, 35 : 43 - 50
  • [5] Pharmacokinetics, excretion, distribution, and metabolism of 60-kDa polyethylene glycol used in BAY 94-9027 in rats and its value for human prediction
    Baumann, Andreas
    Piel, Isabel
    Hucke, Frank
    Sandmann, Steffen
    Hetzel, Terence
    Schwarz, Thomas
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 130 : 11 - 20
  • [6] Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A with inhibitors-A retrospective analysis
    Carcao, M.
    Shapiro, A.
    Staber, J. M.
    Hwang, N.
    Druzgal, C.
    Lieuw, K.
    Belletrutti, M.
    Thornburg, C. D.
    Ahuja, S. P.
    Morales-Arias, J.
    Dumont, J.
    Miyasato, G.
    Tsao, E.
    Jain, N.
    Pipe, S. W.
    [J]. HAEMOPHILIA, 2018, 24 (02) : 245 - 252
  • [7] Prophylactic factor replacement in hemophilia
    Carcao, MD
    Aledort, L
    [J]. BLOOD REVIEWS, 2004, 18 (02) : 101 - 113
  • [8] Chen SL, 2016, AM J MANAG CARE, V22, pS126
  • [9] Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A
    Coyle, T. E.
    Reding, M. T.
    Lin, J. C.
    Michaels, L. A.
    Shah, A.
    Powell, J.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2014, 12 (04) : 488 - 496
  • [10] Once-weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8-GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial)
    Curry, Nicola
    Albayrak, Canan
    Escobar, Miguel
    Holme, Pal Andre
    Kearney, Susan
    Klamroth, Robert
    Misgav, Mudi
    Negrier, Claude
    Wheeler, Allison
    Santagostino, Elena
    Shima, Midori
    Landorph, Andrea
    Tonder, Sidsel Marie
    Lentz, Steven R.
    [J]. HAEMOPHILIA, 2019, 25 (03) : 373 - 381
1234567